Pfizer Inc (PFE): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Pfizer ( PFE) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 1.7%. By the end of trading, Pfizer fell 24 cents (-1%) to $23.81 on average volume. Throughout the day, 31.2 million shares of Pfizer exchanged hands as compared to its average daily volume of 27.1 million shares. The stock ranged in price between $23.74-$24.10 after having opened the day at $24.07 as compared to the previous trading day's close of $24.05. Other companies within the Drugs industry that declined today were: AVEO Pharmaceuticals ( AVEO), down 14.1%, Medgenics ( MDGN), down 11.9%, Catalyst Pharmaceutical Partners ( CPRX), down 10.8%, and Acura Pharmaceuticals ( ACUR), down 9.1%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Pfizer Inc., a biopharmaceutical company, engages in the discovery, development, manufacture, and sale of medicines for people and animals worldwide. Pfizer has a market cap of $177.51 billion and is part of the health care sector. The company has a P/E ratio of 18.7, above the S&P 500 P/E ratio of 17.7. Shares are up 11.4% year to date as of the close of trading on Tuesday. Currently there are 14 analysts that rate Pfizer a buy, no analysts rate it a sell, and two rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!.

null

More from Markets

Dow Set to Snap 8-Day Losing Streak as Stocks Recover, But Trade War Lingers

Dow Set to Snap 8-Day Losing Streak as Stocks Recover, But Trade War Lingers

OPEC, Bank Stress Tests, Disney and Tesla - 5 Things You Must Know

OPEC, Bank Stress Tests, Disney and Tesla - 5 Things You Must Know

Big Banks Pass the Stress Tests and 4 Other Stories to Watch Friday Morning

Big Banks Pass the Stress Tests and 4 Other Stories to Watch Friday Morning

OPEC Debating 1 Million Barrel Oil Market Boost as Iran Signals Support

OPEC Debating 1 Million Barrel Oil Market Boost as Iran Signals Support

Foxconn Chairman Terry Gou: US and China Are Waging a Global 'Tech War'

Foxconn Chairman Terry Gou: US and China Are Waging a Global 'Tech War'